On December 23, 2024, Corxel Pharmaceuticals in-licensed the global development and commercialization rights (excluding Greater China) for CX11 (also known as VCT220) from Vincentage.Currently, Corxel holds global rights to three products and Greater China rights to two products.

In response to this dilemma, Micro X-ray Technology has built a complete molybdenum-based liquid bearing production line and achieved stable mass production of liquid bearing CT ball tubes. As a result, Micro X-ray Technology has built a barrier from ball bearings to liquid metal bearings.

This drug candidate is intended for the prophylactic protection against food allergens and is currently in Phase IIb clinical development. Pursuant to the agreement, GSK will obtain the global rights (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop and commercialize ozureprubart. Concurrently, GSK will assume the responsibility for future success-based milestone and royalty payments owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd.

The anti-aging market commonly faces challenges such as fragmented products and services, difficulties in quantitatively evaluating the effectiveness of interventions, and a lack of standardized systems. These issues often leave users caught in a dilemma of "wanting to believe but hesitating to trust.

NewDEL Biotech specializes in the in-depth development and application of DNA-encoded library (DEL) technology, and is dedicated to empowering and advancing innovative drug research and development through its distinct technological capabilities.

Rejuve Biotechnology is an innovative company focused on the research, development, production, and sales of recombinant botulinum toxin. It is committed to applying synthetic biology technology to the field of pharmaceuticals, developing and providing botulinum toxin series products with outstanding cost-effectiveness, with the aim of becoming one of the leading suppliers in this category.

ISM8969 is a novel, orally available NLRP3 inhibitor with blood-brain barrier penetration properties, discovered and optimized through Insilico Medicine's generative chemistry platform Chemistry42. Preclinical studies have demonstrated its excellent efficacy, favorable safety profile, and superior blood-brain barrier penetration capability.

C-CAR031 is an autologous, Glypican-3 (GPC3)-targeting chimeric antigen receptor T-cell (CAR-T) therapy. Based on AstraZeneca's novel GPC3-targeting CAR-T candidate (AZD5851), it is designed using AstraZeneca's dominant negative transforming growth factor-beta receptor II (dnTGFβRII) armoring platform and is manufactured by AbelZeta in China. It is currently being investigated for the treatment of hepatocellular carcinoma (HCC) and other solid tumors.

Preliminary statistics from VCBeat identified 16 financing events in China's healthcare sector between January 12 and 16, 2026 (excluding IPOs and private placements). The period was headlined by Zenitar‘s nearly RMB 600 million Series C round, followed by Oricell Therapeutics' USD 70 million Series C round.

As a global leader in providing solutions for live single-cell metabolic function analysis and sorting, Single-Cell Biotech leverages its proprietary and innovative "Meta-Ramanome Technology" as the core platform. Single-Cell Biotech has successfully developed a high-end product portfolio of live single-cell "metabolic profiling" instruments that target specific metabolic functions.

Interestingly, after finalizing the collaboration on December 16, Yarrow promptly announced a reverse merger with VYNE Therapeutics on December 17, completing a backdoor listing with the stock symbol "YARW". According to the merger agreement, shareholders of Yarrow are expected to own approximately 97% of the combined company, while shareholders of VYNE are expected to own approximately 3%.

Sinus Medtech's core product, the "Ventricular Septum Radiofrequency Ablation System," has been included in the National Innovative Medical Device Special Review Process and has received the FDA's Breakthrough Device designation, reflecting its recognized clinical value.

Precision is a global leader in invasive brain-computer interfaces and a major competitor to the well-known Neuralink, owned by Musk. Its Layer 7 brain-computer interface, which utilizes a high-resolution cortical electrode array, received FDA approval in April of last year. It can be implanted into patients' brains for up to 30 days, enabling individuals with severe paralysis to control electronic devices such as computers and smartphones through their thoughts.

Against the backdrop of the rapid development of the global biopharmaceutical industry and the increasingly urgent demand for autonomous and controllable supply chains, Alioth has remained dedicated since its establishment to the research, development, manufacturing, and application of critical filtration membranes and single-use filter products essential in biopharmaceutical processes.

Since its establishment at the end of 2020, Signet Therapeutics has centered its efforts around a forward-looking "organoids + AI" drug R&D platform, dedicated to addressing the major unmet clinical needs of malignant metastatic cancers such as diffuse gastric cancer, liver cancer, and lung cancer.

Since its inception, XellSmart has assembled a fully dedicated, internationally competitive professional team focused on the R&D of iPSC-derived cell-based therapeutics. The team covers the core aspects of R&D and industrialization for iPSC-derived neural cell drugs.

As a biotech company driven by independent innovation, Genhouse Bio remains focused on developing globally leading targeted anti-tumor small-molecule therapeutics. Genhouse Bio has established a drug development philosophy centered on "AI/Biology-Driven Smart Design," deeply integrating computational chemistry, artificial intelligence, and internal experimental platforms to form an efficient R&D system characterized by "data-driven, rapid iteration."

Given the complexity of the CNS and the challenges in drug development, there remains a substantial unmet clinical need for many CNS diseases. With continuous advancements in sophisticated research instruments, fundamental research in the CNS field has reached a tipping point.

Beyond its pain management projects, Biyo Pharma continues to strategically invest in several other key areas, including chronic pain, neurorestoration, metabolism, and immune inflammation. This provides the company with sustained innovation momentum and a pipeline reserve for its medium- to long-term development.

Haisco Pharmaceutical stated that, unlike the previous straightforward "License-out" model, this collaboration involved the establishment of a new entity (NewCo), enabling deep alignment and mutual growth with AirNexis and its investors. This move marks a further upgrade in Haisco's internationalization strategy.